Alliance for Regenerative Medicine

Stance on Human Embryonic Stem Cells


- In 2017, the Alliance for Regenerative Medicine issued a statement about gene-editing technology in human embryos in the US. They said: “ARM continues to monitor the latest developments in gene-editing technologies, given their enormous medical potential. We reiterate our encouragement and support of the use of these technologies in somatic (non-reproductive) human cells to durably treat and potentially cure human diseases. Patients will benefit more immediately from resources being directed towards somatic applications of the technologies at this time, as most genetic diseases manifest in and can be treated in somatic, not germline, cells. In addition, many unresolved safety, ethical and legal issues remain with human germline engineering approaches.”

https://alliancerm.org/bioethics/stem-cell-clinical-trials/

- The Alliance for Regenerative Medicine states that it “supports regulatory oversight and review of Human Cells, Tissues and Cellular and Tissue-based Products (HCT/Ps) that are more than minimally manipulated and not for homologous use.”

https://alliancerm.org/

- “Regenerative medicine includes gene therapies, cell therapies, and tissue-engineered products intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body.”

https://alliancerm.org/sector-snapshot/

- In their 2023 Snapshot catalogue, ARM states that are conducting research using the controversial CRISPR method.

https://alliancerm.org/arm-staff/

- ARM’s current CEO, Timothy Hunt, served as Chief Corporate Affairs Officer at CRISPR gene-editing pioneer Editas Medicine.
While researching the former Coalition for the Advancement of Medical Research, American Life League discovered on CAMR's former website that as of May 21, 2013, they transferred their “mission and its assets” to ARM. The next paragraph on their website says the following:

♦ "Human embryonic stem cell research has grown and evolved to a point where it's time for CAMR to hand off its mission to an organization that can advance policy initiatives to support where the science is now, and where it is headed," said CAMR president Amy Comstock Rick, J.D. "Following President Obama's March 2009 Executive Order and subsequent National Institutes of Health stem cell research guidelines, we've seen the number of human embryonic stem cell research lines on the NIH registry grow from just 21 in 2008 to more than 200 today. The science is strong, and government research funding continues to strengthen the field. The private sector is moving the research forward into patient therapies and treatments, and the Alliance for Regenerative Medicine is absolutely the right organization to shepherd stem cell policy support to the next level."

♦ Since ARM has not responded to ALL’s inquiries, and there has not been a change to their human embryonic stem cells statement since the transition from CAMR in 2013, we cannot recommend supporting ARM and their work.